- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.05. | Artiva reports promising AlloNK therapy results in B-NHL study | 1 | Investing.com | ||
| 13.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT ... | 40 | GlobeNewswire (Europe) | 64% (9/14) complete response rate with AlloNK + rituximab in heavily pretreated patients that were naïve to prior CAR-T cell therapy, in line with approved auto-CAR-T therapies in aggressive B-NHL... ► Artikel lesen | |
| ARTIVA BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.05. | Artiva Biotherapeutics GAAP EPS of -$0.83 | 2 | Seeking Alpha | ||
| 08.05. | Artiva Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights | 89 | GlobeNewswire (Europe) | IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis ... ► Artikel lesen | |
| 08.05. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.04. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 08.04. | Artiva Biotherapeutics names new Chief Medical Officer | 2 | Investing.com | ||
| 08.04. | Artiva Biotherapeutics ernennt neuen Chief Medical Officer | 4 | Investing.com Deutsch | ||
| 08.04. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer | 592 | GlobeNewswire (Europe) | SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies... ► Artikel lesen | |
| 26.03. | Artiva Biotherapeutics stock rises following analyst optimism | 1 | Investing.com | ||
| 26.03. | Artiva Biotherapeutics-Aktie steigt nach Analysten-Optimismus | 2 | Investing.com Deutsch | ||
| 24.03. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights | 105 | GlobeNewswire (Europe) | Initial data for AlloNK® from autoimmune program expected H1 2025 Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented... ► Artikel lesen | |
| 24.03. | Artiva Biotherapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 24.03. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 29.01. | Artiva Biotherapeutics expands board with industry veteran | 3 | Investing.com | ||
| 29.01. | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. | 1 | GlobeNewswire (USA) | ||
| 29.01. | Artiva Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 29.08.24 | Artiva Biotherapeutics, Inc.: Artiva Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights | 296 | GlobeNewswire (Europe) | Strong balance sheet with successful completion of upsized $179.0 million initial public offering Treatment initiated in the first patient in an investigator-initiated basket trial of AlloNK® exploring... ► Artikel lesen | |
| 19.07.24 | Artiva Biotherapeutics Prices Upsized IPO Of About 13.92 Mln Shares At $12.00/shr | 740 | AFX News | WASHINGTON (dpa-AFX) - Artiva Biotherapeutics, Inc. (ARTV) announced the pricing of its upsized initial public offering of about 13.92 million shares of common stock at a price to the public... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
| CUREVAC | 3,830 | -0,83 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
| AMGEN | 254,90 | +0,08 % | Amgen Says Imdelltra Cut Risk Of Death By 40% In Small Cell Lung Cancer Patients | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) Monday announced positive interim results from the Phase 3 DeLLphi-304 study showing Imdelltra reduced the risk of death by 40% and significantly... ► Artikel lesen | |
| NOVAVAX | 6,520 | -0,20 % | Aktien New York: Rücksetzer nach US-Bonitätsabstufung verpufft | NEW YORK (dpa-AFX) - Die Abstufung der US-Kreditwürdigkeit durch Moody?s hat die Anleger in New York am Montag nicht lange beeindruckt. Benoit Anne, Anleiheexperte bei MFS Investment Management, verwies... ► Artikel lesen | |
| BIOGEN | 116,70 | -0,09 % | DAX tritt auf der Stelle - Nvidia & Biogen mit Überraschung! Gold, EUR & Aktien im Chartcheck | ||
| MAINZ BIOMED | 2,775 | -100,00 % | MAINZ BIOMED N.V. - 6-K, Report of foreign issuer | ||
| VIKING THERAPEUTICS | 24,220 | -0,78 % | Viking Therapeutics auf Jefferies-Konferenz: Vielversprechendes Abnehm-Medikament | ||
| INTELLIA THERAPEUTICS | 7,146 | +0,37 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 9,668 | -0,17 % | BioCryst Pharmaceuticals, Inc.: BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries | RESEARCH TRIANGLE PARK, N.C., June 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland... ► Artikel lesen | |
| TEMPUS AI | 54,74 | +0,51 % | Opening Bell: Constellation Energy, Vistra, Netflix, Applied Digital, Steel Dyn., Pony.ai, Tempus AI | Zum Wochenauftakt schwankten die US-Börsen zwischen neuen Zolldrohungen und der Hoffnung auf sinkende Zinsen. Zwar sorgte US-Präsident Trumps verschärfte Rhetorik im Handelsstreit mit China zunächst... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 38,180 | +1,17 % | FDA Grants Platform Technology Status To Sarepta's RAAVrh74 Vector | WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT), Wednesday announced that the FDA has designated its rAAVrh74 viral vector used in the investigational gene therapy SRP-9003 for limb-girdle... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,218 | -1,30 % | H.C. Wainwright initiates Cardiol Therapeutics stock with buy rating | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,000 | +1,26 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
| EXELIXIS | 37,400 | -0,93 % | BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution | ||
| VAXART | 0,364 | +2,42 % | Vaxart, Inc.: Vaxart Announces Adjournment of Annual Meeting of Stockholders |
Das Unternehmen ARTIVA BIOTHERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,105 (+5,36 %) liegt der Kurs bei 2,065 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ARTIVA BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.